Taldaev A et al., 2023-09-28: PRISMA systematic review (PROSPERO CRD42022368738) of preclinical studies of methylene blue photodynamic therapy in cancer. Ten animal studies met inclusion; seven reported tumour-size decreases of 12.0% to 100.0%, while three (breast cancer and HeLa models) showed no tumour reduction but slower growth than controls.
It was confirmed by decreases in tumor sizes reported in seven articles from 12.0% to 100.0%.
Taldaev A et al., 2023-09-28: PRISMA systematic review (PROSPERO CRD42022368738) of preclinical studies of methylene blue photodynamic therapy in cancer. Ten animal studies met inclusion; seven reported tumour-size decreases of 12.0% to 100.0%, while three (breast cancer and HeLa models) showed no tumour reduction but slower growth than controls. Study type: systematic review of preclinical (animal) studies, PRISMA, narrative synthesis, no meta-analysis. N: 10 included studies, all animal models (no human studies). Country: Russia (Sechenov University / Institute of Biomedical Chemistry, Moscow); PROSPERO CRD42022368738. MB dose across studies: 0.04 to 24.12 mg/kg, injected, 1 to 7 intakes, 8 to 35 days; formulations plain MB or nanoformulations (nano graphene oxide, liposome nanoplatform, colloidal nanoformulation, nanosheets). Light parameters vary by study and are tabulated in Table 2 rather than pooled. Cancer models: non-melanoma skin cancer, breast cancer (3 studies), malignant melanoma, colorectal tumour (2), adenocarcinoma, HeLa, carcinoma. Comparator: untreated/vehicle control groups. Funding: Ministry of Science and Higher Education of the Russian Federation, World-Class Research Centres 'Digital Biodesign and Personalized Healthcare' No. 075-15-2022-305. Conflicts: authors declare none. Maker: no commercial product specified; MB source not stated. The review states 'the baseline study showed a low affinity of MB to cancer cells' (citing Kofler et al. 2018) and that pharmacokinetics require in vivo examination before clinical translation; risk-of-bias assessment found allocation concealment, random housing, blinding and random outcome assessment largely unreported, increasing performance/detection/reporting bias. Search was PubMed only. CORRECTION for the run brief: the review covers TEN articles, not seven; seven is the subset reporting tumour-size decreases. Includes no human data. Also filed as MTG-074 (claims C1, C15). Study type: review.
